Clinical Trial Update: A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of Adjuvant Intismeran Autogene (V940) with pembrolizumab in renal cell carcinoma; the study is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Intismeran Autogene (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING